Equillium, Inc. filings document a clinical-stage biotechnology issuer focused on therapies for severe autoimmune and inflammatory disorders. The company’s disclosures cover EQ504, an investigational AhR modulator, along with operating results, financial condition, research and development priorities, and capital resources tied to biotechnology development.
Regulatory filings include 8-K material-event reports, proxy materials, and registration-related disclosures. These records address annual-meeting matters, board and compensation governance, equity awards, auditor changes, common-stock offering documents, material agreements, shareholder voting matters, and capital-structure information for EQ common stock listed on the Nasdaq Capital Market.
Equillium, Inc. Schedule 13G/A: ADAR1-related entities and Daniel Schneeberger report indirect beneficial ownership of common stock as of March 31, 2026. ADAR1 Capital Management, LLC is shown with 6,603,754 shares (9.9%); ADAR1 Capital Management GP, LLC with 6,306,184 shares (9.5%). The filing cites 63,226,556 shares outstanding as of March 31, 2026 per the issuer's Form 10-Q. The cover disclosures list constituent holdings and 2,877,095 shares underlying prefunded warrants, and note 557,415 prefunded-warrant shares excluded due to a 9.99% beneficial ownership limitation. The filing states these holdings are indirect, reflecting ADAR1’s roles as investment manager, general partner, and Mr. Schneeberger’s manager/control-person status.
Decheng Capital entities and Xiangmin Cui filed an amendment to a Schedule 13G/A reporting beneficial ownership of common stock of EQ. The filing states ownership figures "as of March 31, 2026" and ties the percentage calculations to March 20, 2026 outstanding shares.
The filing says Fund IV directly holds "3,285,710 shares" and warrants exercisable for "985,713 shares," and Healthcare directly holds "1,161,598 shares" and warrants exercisable for "300,000 shares." The cover rows report 5,733,021 shares (8.9%) for Dr. Cui based on "63,226,556 shares outstanding as of March 20, 2026." Signatures show the report was signed on 05/15/2026.
Equillium, Inc. reported a net loss of $5.3M for the quarter ended March 31, 2026, narrowing from $8.7M a year earlier as research and development spending declined after winding down prior clinical programs. Operating expenses fell to $5.6M from $8.9M, driven mainly by lower clinical and headcount-related costs.
Cash and cash equivalents increased to $61.3M at March 31, 2026 from $30.3M at year-end 2025, primarily due to a March 2026 private placement that raised gross proceeds of about $35.0M through common stock and a large pre-funded warrant. Management believes this cash can fund operations into 2029, but the company still has an accumulated deficit of $221.5M and has not generated product revenue.
Equillium’s main focus is advancing EQ504, a novel aryl hydrocarbon receptor modulator, with plans to start a Phase 1 proof-of-mechanism study in mid-2026 and target ulcerative colitis and other gastrointestinal diseases. Additional preclinical work continues on EQ302 and a multi-cytokine platform, while significant potential future dilution exists from pre-funded warrants, stock options and an unused at-the-market equity program.
Equillium, Inc. reported first quarter 2026 results and highlighted progress on its immunology pipeline, led by EQ504. For the quarter ended March 31, 2026, net loss was $5.3 million, or $(0.06) per share, improving from a net loss of $8.7 million, or $(0.24) per share, a year earlier as operating expenses declined.
Research and development expenses fell to $3.0 million from $5.9 million, mainly due to winding down prior clinical studies, while general and administrative expenses declined to $2.6 million from $2.9 million on lower legal and professional fees. Cash and cash equivalents increased to $61.3 million as of March 31, 2026 from $30.3 million at year-end 2025, helped by a $35 million private placement completed in March.
The company expects its cash position to fund currently planned operations into 2029. Equillium plans to start a Phase 1 proof-of-mechanism study of EQ504 in mid-2026, with data anticipated about six months later, and is also evaluating further advancement of its EQ302 program.
Aberdeen Group plc reported beneficial ownership of 3,352,837 shares of Equillium, Inc. common stock, representing 5.30% of the class. The filing states Aberdeen Group plc and abrdn Inc. hold shared voting and dispositive power over 3,352,837 shares and that abrdn Inc. holds these shares on behalf of underlying clients. The filing lists CUSIP 29446K106 and is signed by Romiza Chaudhry on 05/07/2026.
Equillium, Inc. is asking stockholders to vote at a virtual annual meeting on May 28, 2026. Key items include electing two Class II directors to serve until the 2029 meeting, approving a reverse stock split at a ratio between 1-for-2 and 1-for-20, ratifying Crowe LLP as independent auditor for 2026, and amending the charter to increase authorized common stock from 200,000,000 to 400,000,000 shares. Stockholders of record as of April 1, 2026, when 63,226,556 shares of common stock were outstanding, may vote online, by phone, internet or mail.
Equillium, Inc. is registering 18,878,101 shares of common stock for resale by a selling stockholder. The registration covers 1,179,508 shares sold in a private placement and a pre-funded warrant exercisable for 17,698,593 shares. We will receive no proceeds from resales under this prospectus.
The private placement closed March 13, 2026 for approximately $35.0 million; the pre-funded warrant has a per-share exercise price of $0.0001 and includes a specified beneficial ownership limitation. Shares may be sold in various ways including block trades, market transactions or through underwriters; the selling stockholder listed is RA Capital Healthcare Fund, L.P..
Equillium, Inc. is soliciting proxies for its virtual 2026 annual meeting on May 28, 2026 to vote on director elections and corporate charter amendments.
Stockholders of record as of April 1, 2026 may vote. Key proposals include electing two Class II directors, authorizing a board‑discretion reverse stock split at a ratio in the range of 1‑for‑2 to 1‑for‑20, ratifying Crowe LLP as independent auditors for fiscal 2026, and increasing authorized common shares from 200,000,000 to 400,000,000. The Board may implement an approved reverse split at any time on or prior to December 31, 2027.